IPH 2101: Interim Phase I data

Interim data from the open-label, U.S. Phase I KIRIMID trial in 14 patients with relapsed MM after 1-2 prior lines of therapy showed that IV IPH2101 on day 1 plus Revlimid lenalidomide on days 1-21 of a 28-day cycle produced 1 unconfirmed complete response, 3 partial responses, 2 minor responses and 1 case of stable disease. Dose-limiting toxicities (DLTs) included 2 cases of severe leucopenia at the 0.2 and 1 mg/kg doses of IPH2101. There were 4 serious adverse events reported, of which 3 were possibly or probably related to IPH2101 and/or Revlimid. The MTD has not yet been identified. The 14 patients received 0.2 mg/kg IPH2101 plus 10 mg Revlimid, 0.2 mg/kg IPH2101 plus 25 mg Revlimid or 1 mg/kg IPH2101 plus 25 mg Revlimid. The trial will also enroll 3 patients to receive 2 mg/kg IPH2101 plus 25 mg Revlimid and 6 patients to receive the MTD. Data were presented at the American Society of Hematology meeting in Atlanta. ...